cTRL Therapeutics is pioneering a novel approach to solid tumor cancer therapies by harnessing the power of circulating tumor-reactive lymphocytes (cTRLs), a rare and potent subset of CD8+ T cells found in the bloodstream. These cTRLs are characterized by their polyclonality, allowing them to recognize multiple tumor antigens across various cancers, which is crucial for effective treatment. The company’s proprietary IsoQore™ technology enables the efficient isolation and extraction of these cTRLs from a single blood draw, preserving their viability and functionality. This method not only simplifies the process of obtaining therapeutic cells compared to traditional approaches that require invasive surgical procedures but also enhances the quality and quantity of the extracted cells, making it a scalable solution for solid tumor therapies.

The cTRL-based therapies developed by cTRL Therapeutics aim to address the limitations of existing treatments, such as tumor-infiltrating lymphocytes (TILs) and T cell receptor (TCR) therapies, which often involve complex and invasive procedures. By focusing on non-genetically modified cTRLs, the company’s lead asset, cTRL-001, seeks to combine the advantages of existing therapies while minimizing their drawbacks. This innovative approach not only promises to improve the effectiveness of solid tumor treatments but also aims to streamline manufacturing processes and reduce adverse effects, ultimately paving the way for a new generation of cancer therapies that can benefit a broader patient population.

United States

We are building a new company to transform the cell therapy space by developing autologous cell therapies for patients with solid tumors. We are building a company culture based on collaboration, transparency, integrity, and commitment to excellence. We are looking for passionate people to be a part of this journey.

cTRL Therapeutics

Company Details